Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1998;25(4):294–297.

Treatment of advanced heart failure in a young man with familial cardiomyopathy.

E K Massin 1
PMCID: PMC325575  PMID: 9885106

Abstract

We report the case of a young man with familial cardiomyopathy whose symptoms became difficult to control as his myopathy worsened. He had persistent cardiac arrhythmias and was intolerant of angiotensin-converting enzyme inhibitor therapy. His case illustrates the difficulties that can be encountered in treating patients with advanced heart failure.

Full text

PDF
294

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Khadra A. S., Salem D. N., Rand W. M., Udelson J. E., Smith J. J., Konstam M. A. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998 Mar 15;31(4):749–753. doi: 10.1016/s0735-1097(98)00006-0. [DOI] [PubMed] [Google Scholar]
  2. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  3. Doval H. C., Nul D. R., Grancelli H. O., Perrone S. V., Bortman G. R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet. 1994 Aug 20;344(8921):493–498. doi: 10.1016/s0140-6736(94)91895-3. [DOI] [PubMed] [Google Scholar]
  4. Dries D. L., Rosenberg Y. D., Waclawiw M. A., Domanski M. J. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997 Apr;29(5):1074–1080. doi: 10.1016/s0735-1097(97)00019-3. [DOI] [PubMed] [Google Scholar]
  5. Fonarow G. C., Chelimsky-Fallick C., Stevenson L. W., Luu M., Hamilton M. A., Moriguchi J. D., Tillisch J. H., Walden J. A., Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992 Mar 15;19(4):842–850. doi: 10.1016/0735-1097(92)90529-v. [DOI] [PubMed] [Google Scholar]
  6. Holmes J., Kubo S. H., Cody R. J., Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol. 1985 Jan 1;55(1):146–151. doi: 10.1016/0002-9149(85)90317-0. [DOI] [PubMed] [Google Scholar]
  7. Koniaris L. S., Goldhaber S. Z. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol. 1998 Mar 15;31(4):745–748. doi: 10.1016/s0735-1097(98)00003-5. [DOI] [PubMed] [Google Scholar]
  8. Meinertz T., Hofmann T., Kasper W., Treese N., Bechtold H., Stienen U., Pop T., Leitner E. R., Andresen D., Meyer J. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol. 1984 Mar 15;53(7):902–907. doi: 10.1016/0002-9149(84)90522-8. [DOI] [PubMed] [Google Scholar]
  9. Nisam S., Mower M. ICD trials: an extraordinary means of determining patient risk? Pacing Clin Electrophysiol. 1998 Jul;21(7):1341–1346. doi: 10.1111/j.1540-8159.1998.tb00203.x. [DOI] [PubMed] [Google Scholar]
  10. Nul D. R., Doval H. C., Grancelli H. O., Varini S. D., Soifer S., Perrone S. V., Prieto N., Scapin O. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. J Am Coll Cardiol. 1997 May;29(6):1199–1205. doi: 10.1016/s0735-1097(97)00066-1. [DOI] [PubMed] [Google Scholar]
  11. Petersen P., Boysen G., Godtfredsen J., Andersen E. D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989 Jan 28;1(8631):175–179. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
  12. Siebels J., Kuck K. H. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994 Apr;127(4 Pt 2):1139–1144. doi: 10.1016/0002-8703(94)90101-5. [DOI] [PubMed] [Google Scholar]
  13. Singh S. N., Fletcher R. D., Fisher S. G., Singh B. N., Lewis H. D., Deedwania P. C., Massie B. M., Colling C., Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995 Jul 13;333(2):77–82. doi: 10.1056/NEJM199507133330201. [DOI] [PubMed] [Google Scholar]
  14. Vaitkus P. T., Barnathan E. S. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993 Oct;22(4):1004–1009. doi: 10.1016/0735-1097(93)90409-t. [DOI] [PubMed] [Google Scholar]
  15. von Olshausen K., Schäfer A., Mehmel H. C., Schwarz F., Senges J., Kübler W. Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J. 1984 Feb;51(2):195–201. doi: 10.1136/hrt.51.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES